Growth investing strategies often look for companies with strong earnings momentum, market leadership, and sound financials. One established method for this search is the CAN SLIM system, made known by investor William O’Neil. This method joins fundamental analysis to locate high-growth companies with technical analysis to time entries during good market conditions. The system’s acronym lists important criteria: Current quarterly earnings acceleration, Annual earnings growth, New products or highs, Supply and demand dynamics, Leadership in its sector, Institutional sponsorship, and overall Market direction.
A recent filter using main CAN SLIM rules has identified Viemed Healthcare Inc (NASDAQ:VMD) as a possible choice for investors using this strategy. The company provides in-home respiratory care, sleep apnea testing, and healthcare staffing services, operating in the increasing home healthcare sector.
Meeting the CAN SLIM Criteria
The CAN SLIM framework gives a structured checklist. Based on the given data, Viemed Healthcare seems to meet several of its numerical requirements:
- Current Quarterly Earnings & Sales (The "C"): A central part of CAN SLIM is strong recent momentum. VMD reports a quarterly earnings per share (EPS) growth of 40.0% and sales growth of 25.5% compared to the same quarter last year. This passes the usual system minimums of 20-25%, showing solid current operational momentum.
- Annual Earnings Increases (The "A"): The system wants a proven history of growth. VMD shows a 3-year EPS compound annual growth rate (CAGR) of about 35.1%, clearly above the 25% mark often used. Also, its Return on Equity (ROE) of 10.2% meets the minimum level for profitability efficiency.
- Leadership & Relative Strength (The "L"): CAN SLIM investors look for market leaders, not followers. This is measured by relative strength, which compares a stock's price performance against the wider market. VMD's relative strength of 84.6 puts it in the top 15% of all stocks, a good sign of institutional support and price leadership.
- Institutional Sponsorship (The "I"): While institutional ownership is needed, it should not be so high that all possible buying is done. VMD's institutional ownership of about 67% is under the 85% limit, indicating space for more institutional buying.
- Supply & Demand / Financial Health (The "S"): The system prefers companies with strong balance sheets. VMD keeps a careful Debt-to-Equity ratio of 0.15, which is far below the maximum limit of 2. This shows low financial risk and matches the preference for manageable share supply and financial steadiness.
Fundamental and Technical Summary
A look at Viemed's separate reports gives a wider view for its CAN SLIM fit.
The fundamental analysis report gives VMD a neutral rating of 5 out of 10. It points out the company's good profitability ratios and very solid balance sheet with little debt. However, it notes some pressure on profit margins in recent years. Valuation seems mixed, with a forward P/E ratio that is high in absolute terms but fair relative to both its industry and the S&P 500, especially when looking at its high expected future earnings growth.
The technical analysis report is clearly stronger, giving a rating of 9 out of 10. It confirms the stock is in a positive long-term and short-term trend, a key part of the "M" (Market Direction) in CAN SLIM. Significantly, the stock is trading near new 52-week highs, a main technical feature the system seeks. The report does warn that recent price swings may make finding a clear entry point difficult, advising patience for a good setup.
A Candidate for Further Research
Viemed Healthcare makes a strong case for investors using the CAN SLIM growth strategy. It meets multiple fundamental points with its increasing quarterly earnings, good annual growth history, high relative strength, and solid financial health. Technically, the stock is in a confirmed uptrend and showing leadership. While the fundamental rating indicates areas of neutral performance, the main growth profile and technical momentum fit with the system's central idea of investing in leading companies during their growth phase.
It is important to recall that a filter result is a beginning for more detailed examination. The CAN SLIM method also stresses qualitative reviews of a company's "New" products or services, in Viemed's case, its focus on in-home respiratory care, and needs a positive overall market view.
This filtering process can be copied to locate other possible ideas. You can view the live CAN SLIM filter used in this study here to see current results and change the rules based on your own investment settings.
Disclaimer: This article is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer or solicitation to buy or sell any securities. The analysis presented is based on data provided and should not be the sole basis for any investment decision. All investing involves risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.